Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sustained-release oral morphine for sleep and breathlessness in chronic obstructive pulmonary disease
ACTRN12621000752864Phase 2Completed
- Sponsor
- Adelaide Institute for Sleep Health
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of morphine in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Adelaide Institute for Sleep Health. Primary endpoint: Sleep efficiency. Started Sep 2021; status: completed.
02
Drugs
morphine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12621000752864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000752864.